BR9813474A - Processo para intensificar uma absorção pelo animal de pelo menos um composto lipofìlico, e, composição - Google Patents

Processo para intensificar uma absorção pelo animal de pelo menos um composto lipofìlico, e, composição

Info

Publication number
BR9813474A
BR9813474A BR9813474-4A BR9813474A BR9813474A BR 9813474 A BR9813474 A BR 9813474A BR 9813474 A BR9813474 A BR 9813474A BR 9813474 A BR9813474 A BR 9813474A
Authority
BR
Brazil
Prior art keywords
animal
weight
carbon atoms
absorption
acyl
Prior art date
Application number
BR9813474-4A
Other languages
English (en)
Inventor
Stephen J Demichele
Theresa W Lee
Patrick Tso
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9813474A publication Critical patent/BR9813474A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/10—Ester interchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

''PROCESSO PARA INTENSIFICAR UMA ABSORçãO PELO ANIMAL DE PELO MENOS UM COMPOSTO LIPOFìLICO, E, COMPOSIçãO" Esta invenção diz respeito a um processo para intensificar a absorção de compostos solúveis em óleo (lipofílicos) tais como vitaminas solúveis em óleo, hormónios, nutrientes e medicamentos em um animal. O processo da invenção compreende a administração de um composto lipofílico em conjunto com um componente de glicerídeo estruturado caracterizado pelo fato de que pelo menos 40% das espécies de glicerídeo têm: (i) cerca de 33 a 70% em peso de porções de acila tendo de 4 a 12 átomos de carbono; (ii) cerca de 30 a 67% em peso de porções de acila tendo mais do que 12 átomos de carbono; e (iii) uma quantidade de carbono equivalente maior do que 30 e menos do que 48. Esta invenção também diz respeito a composições adequadas para a administração em um animal compreendendo um composto lipofílico e um componente de glicerídeo estruturado, caracterizado pelo fato de que pelo menos 40% das espécies de glicerídeos têm: (i) cerca de 33 a 70% em peso de porções de acila tendo de 4 a 12 átomos de carbono; (ii) cerca de 30 a 67% em peso de proções de acila tendo mais do que 12 átomos de carbono; e (iii) uma quantidade de carbono equivalente maior do que 30 e menos do que 48. O processo e as composições da invenção são especialmente adequadas para animais que sofrem de condições de má absorção do lipídeo tais como a doença de Crohn, fibrose cística, e síndrome do intestino grosso.
BR9813474-4A 1997-12-16 1998-12-04 Processo para intensificar uma absorção pelo animal de pelo menos um composto lipofìlico, e, composição BR9813474A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/991,503 US6013665A (en) 1997-12-16 1997-12-16 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
PCT/US1998/025741 WO1999030740A1 (en) 1997-12-16 1998-12-04 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides

Publications (1)

Publication Number Publication Date
BR9813474A true BR9813474A (pt) 2000-10-10

Family

ID=25537282

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813474-4A BR9813474A (pt) 1997-12-16 1998-12-04 Processo para intensificar uma absorção pelo animal de pelo menos um composto lipofìlico, e, composição

Country Status (19)

Country Link
US (2) US6013665A (pt)
EP (1) EP1037666B1 (pt)
JP (1) JP2002508336A (pt)
AT (1) ATE250938T1 (pt)
AU (1) AU739233B2 (pt)
BR (1) BR9813474A (pt)
CA (1) CA2315224A1 (pt)
DE (1) DE69818704T2 (pt)
DK (1) DK1037666T3 (pt)
ES (1) ES2209228T3 (pt)
HK (1) HK1032744A1 (pt)
HU (1) HUP0100430A2 (pt)
IL (1) IL135271A0 (pt)
NO (1) NO20002306L (pt)
NZ (1) NZ503666A (pt)
PL (1) PL341208A1 (pt)
PT (1) PT1037666E (pt)
TR (1) TR200001563T2 (pt)
WO (1) WO1999030740A1 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE252889T1 (de) * 1998-08-19 2003-11-15 Skyepharma Canada Inc Injizierbare wässerige propofoldispersionen
US6835408B2 (en) 1998-11-13 2004-12-28 The Nisshin Oillio Group, Ltd. Oil or fat composition
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US7211418B2 (en) * 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US20070244192A1 (en) * 1999-01-14 2007-10-18 Martek Biosciences Corporation Plant seed oils containing polyunsaturated fatty acids
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1188440A4 (en) * 1999-06-18 2004-04-14 Yamanouchi Pharma Co Ltd MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
IL135335A (en) * 2000-03-29 2013-12-31 Lycored Natural Prod Ind Ltd Use of Carotenoids in Preparing Pharmaceuticals to Prevent Adverse Effects from Hormones and Pharmaceuticals Containing Carotenoids
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
KR20020081632A (ko) * 2001-04-19 2002-10-30 (주)라이브맥스 Ｃｌａ가 함유된 재구성 지질의 제조방법 및 이용방법
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
JP3980851B2 (ja) * 2001-08-30 2007-09-26 有限会社ゴトーコーポレーション 固型製剤、その製造方法、及び食品
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
US7247334B2 (en) * 2002-03-18 2007-07-24 Bunge Oils, Inc. Low-residue, easy-cleaning and low-viscosity structured lipid pan release compositions and methods
US6793959B2 (en) * 2002-03-18 2004-09-21 Bunge Foods Corporation Low viscosity structured lipid pan release compositions and methods
DE60238663D1 (de) * 2002-04-05 2011-02-03 Nestle Sa Zusammensetzungen und Verfahren zur Verbesserung von Lipidassimilation in Haustieren
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US7041840B2 (en) * 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050196434A1 (en) * 2004-03-04 2005-09-08 Brierre Barbara T. Pharmaceutical composition and method for the transdermal delivery of magnesium
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20050238675A1 (en) * 2004-04-26 2005-10-27 Wenjie Li Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
ES2553101T3 (es) 2004-10-20 2015-12-04 Endorecherche Inc. Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
KR101332869B1 (ko) * 2005-04-15 2013-11-25 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 항-ｅｇｆｒ 치료법에 속발된 피부 발진의 예방 및 치료를위한 비타민 ｋ
EP2985026B1 (en) 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20070218183A1 (en) * 2006-03-14 2007-09-20 Bunge Oils, Inc. Oil composition of conjugated linoleic acid
CA2646317A1 (en) 2006-03-15 2007-09-20 Martek Biosciences Corporation Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
WO2007131802A1 (en) * 2006-05-17 2007-11-22 Ziscoat Nv Fatty acid triglycerides for making biocompatible coatings
WO2008003317A1 (en) * 2006-07-03 2008-01-10 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
CA2558202A1 (en) * 2006-09-14 2006-11-23 Reinhold W. Vieth Vitamin d compositions and method of administration to infants
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8206772B2 (en) * 2007-11-08 2012-06-26 Kraft Foods Global Brands Llc Structured lipid compositions and methods of formulation thereof
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100196554A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to beverages
US9545117B2 (en) * 2009-02-03 2017-01-17 Tropicana Products, Inc. Microencapsulated citrus phytochemicals and application to beverages
US20100196549A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals and application to sports drinks
US20100196577A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to sports drinks
AU2010226440B2 (en) 2009-03-19 2015-08-20 Dsm Ip Assets B.V. Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof
TW201112967A (en) 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (zh) 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
CN102985105B (zh) 2010-01-19 2016-03-09 雅培制药有限公司 包含合生元的营养配方
WO2011126891A2 (en) * 2010-03-30 2011-10-13 Kraft Foods Global Brands Llc Lipid compositions for increased fatty and creamy mouthfeel and uses thereof
EP2397038A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Early programming of brain function through soy protein feeding
EP2422629A1 (en) 2010-08-23 2012-02-29 Abbott Laboratories Methods for enhancing cognition and/or memory using maltodextrins
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9078847B2 (en) 2010-12-29 2015-07-14 Abbott Laboratories Nutritional products including a novel fat system including monoglycerides
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
NL2007268C2 (en) 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US10624916B2 (en) 2012-12-20 2020-04-21 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
US11311512B2 (en) 2014-08-12 2022-04-26 Monash University Lymph directing prodrugs
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CA2997106C (en) 2015-09-08 2024-06-04 Monash University Lymph directing prodrugs
ES2837050T3 (es) 2015-10-01 2021-06-29 Frieslandcampina Nederland Bv Composición nutricional líquida que comprende caseína micelar y proteína de suero de leche hidrolizada
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
AU2018324037A1 (en) 2017-08-29 2020-04-16 Monash University Lymphatic system-directing lipid prodrugs
JP2021501182A (ja) 2017-10-30 2021-01-14 フリースランドカンピーナ ネーデルランド ベスローテン フェンノートシャップ 筋肉量及び／又は筋力の減少に関連する状態を治療及び／又は予防する際の使用のためのタンパク質高密度栄養組成物
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
WO2020052742A1 (en) * 2018-09-11 2020-03-19 Parapharm Development Limited Capsule, tablet or pill
AU2019339536A1 (en) 2018-09-14 2021-04-29 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
US20230149542A1 (en) 2020-04-06 2023-05-18 Abbott Laboratories Nutritional formulations for modulating respiratory-induced cytokines
WO2022177965A1 (en) 2021-02-16 2022-08-25 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en) 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods and compositions for treating gas
WO2023159093A1 (en) 2022-02-16 2023-08-24 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
WO1986001715A1 (en) * 1984-09-13 1986-03-27 Center For Nutritional Research Charitable Trust Triglyceride preparations for the prevention of catabolism
US4753963A (en) * 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
US5081105A (en) * 1988-01-15 1992-01-14 New England Deaconess Hospital Corporation Method of treating cancer using structured lipids
JP2677613B2 (ja) * 1988-06-24 1997-11-17 エーザイ株式会社 ビタミンｅ又はその誘導体の吸収促進組成物
US5601860A (en) * 1990-11-30 1997-02-11 American Home Products Corporation Corandomized fat compositions for infant formulas
WO1992019237A1 (en) * 1991-05-08 1992-11-12 Novo Nordisk A/S Use of a lipid for production of a pharmaceutical enteral preparation for treatment of lipid malabsorption
ES2136189T3 (es) * 1993-01-15 1999-11-16 Abbott Lab Lipidos estructurados.
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
DE4417851C1 (de) * 1994-05-20 1995-10-05 Horst Heirler Diätetisches Lebensmittel mit mittelkettigen Fettsäuren und dessen Verwendung
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia

Also Published As

Publication number Publication date
IL135271A0 (en) 2001-05-20
JP2002508336A (ja) 2002-03-19
US6160007A (en) 2000-12-12
TR200001563T2 (tr) 2000-10-23
HUP0100430A2 (hu) 2001-08-28
DK1037666T3 (da) 2004-02-09
WO1999030740A1 (en) 1999-06-24
HK1032744A1 (en) 2001-08-03
AU739233B2 (en) 2001-10-04
PT1037666E (pt) 2004-02-27
US6013665A (en) 2000-01-11
PL341208A1 (en) 2001-03-26
NO20002306L (no) 2000-06-16
DE69818704T2 (de) 2004-07-29
EP1037666A1 (en) 2000-09-27
EP1037666B1 (en) 2003-10-01
NZ503666A (en) 2002-03-01
NO20002306D0 (no) 2000-04-28
ES2209228T3 (es) 2004-06-16
ATE250938T1 (de) 2003-10-15
AU1625699A (en) 1999-07-05
DE69818704D1 (de) 2003-11-06
CA2315224A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
BR9813474A (pt) Processo para intensificar uma absorção pelo animal de pelo menos um composto lipofìlico, e, composição
BR0308995A (pt) Método de melhorar a absorção de vitamina e por um animal de estimação
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
BE1002710A5 (fr) Preparation au diclofenac sodique a effet prolonge.
BR0213213A (pt) composições farmacêuticas pró-micela
NZ337129A (en) Medical food for diabetics comprising a mixture of linolenic acid and alkanoyl-L-carnitine
ES2137456T3 (es) Agente de tratamiento de las enfermedades hepato-biliares.
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
MX9301835A (es) Composiciones alimenticias de derivado de vitamina d y metodo de uso.
DK0539448T3 (da) Levnedsmiddelsammensætninger og farmaceutiske sammensætninger indeholdende kortkædede, monoumættede fedtsyrer og fremgangsmåde til anvendelse
BR0012303A (pt) Composição de gordura
ES2033985T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
BR9507846A (pt) Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada
KR920700655A (ko) 주사가능한 클라리트로마이신 조성물
PT1216041E (pt) Dieta com elevado teor de lipidos
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
KR930003835A (ko) n-3 지방산이 축적된 돈육 생산용 사료조성물
ES2084328T3 (es) Mezcla de estabilizador.
PT999832E (pt) Composicao compreendendo l-carnitina ou uma l-carnitina de alcanoilo e alcanois de cadeia longa
ES2137927T3 (es) Composicion farmaceutica que contiene mezcla de alcoholes alifaticos primarios superiores para el tratamiento de la hipercolesterolemia y la hiperlipoproteinemia tipo ii, asi como estimulante de la conducta sexual en animales y humanos.
BR0213740A (pt) Processos e composições para uma dieta especifica por gênero de filhotes de animais de estimação
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
DE3368199D1 (en) Mixture comprising a central analgesic and vitamin b12, or one of its analogs, as active principles
KR970705397A (ko) 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B15K Others concerning applications: alteration of classification

Ipc: A23D 9/00 (2006.01), A23L 33/115 (2016.0